2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 54

Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 560

Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 471

Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 760

Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 478

Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 370

Impact of Didactic Lecture on Osteoporosis Screening and Fracture Risk Assessment Among House Staff

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 681

Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from a Prospective, Observational Registry

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 227

Impact of Gout on the Risk of Atrial Fibrillation

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 425

Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 38

Impact of Obesity on the Disease Course of Rheumatoid Arthritis

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 791

Impact of Online Education and Social Media Intervetion for Self-Management in Adolescents with SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 508

Impact of Race on Patient Global Scores and the Misclassification of Disease Activity

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 435

Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 606

Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 838

Impaired Quality of Life in Systemic Sclerosis and Patient Perception of the Disease: A Large International Survey

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].